REGENERON PHARMACEUTICALS, INC. (REGN) Form 8-K — Jul 30, 2026
Regeneron Pharmaceuticals reported financial results for the second quarter of 2026, with total revenues increasing 17% to $4.291 billion compared to the same period in 2025. The company reported GAAP net income per share of $12.23 and non-GAAP net income per share of $14.29, driven by strong commercial performance and operational execution. Product sales showed significant momentum, led by Dupixent global net sales which grew 38% to a record $6.0 billion. EYLEA HD U.S.
Key figures
- Eps
- 12.23
- Revenue
- 4291000000
- Net Income
- 1297000000
- Revenue Yoy
- 17%
- Shares Outstanding
- 106
- Non Gaap Eps
- 14.29
- Eylea Hd Us Sales
- 596000000
- Dividend Per Share
- 0.94
- Libtayo Global Sales
- 489000000
- Share Repurchases Q2
- 1200000000
- Dupixent Global Sales
- 6000000000
Price after filing
Close on the filing date to close N calendar days later (from $695.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.